Corient Private Wealth LLC Has $403,000 Stock Holdings in Penumbra, Inc. (NYSE:PEN)

Corient Private Wealth LLC raised its position in Penumbra, Inc. (NYSE:PEN) by 3.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,695 shares of the company’s stock after acquiring an additional 61 shares during the period. Corient Private Wealth LLC’s holdings in Penumbra were worth $403,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the company. Pallas Capital Advisors LLC lifted its holdings in shares of Penumbra by 3.8% during the 4th quarter. Pallas Capital Advisors LLC now owns 1,108 shares of the company’s stock worth $263,000 after acquiring an additional 41 shares during the period. Advisors Asset Management Inc. raised its position in Penumbra by 11.5% in the third quarter. Advisors Asset Management Inc. now owns 416 shares of the company’s stock worth $81,000 after purchasing an additional 43 shares in the last quarter. Pacer Advisors Inc. lifted its stake in Penumbra by 1.0% during the fourth quarter. Pacer Advisors Inc. now owns 5,721 shares of the company’s stock worth $1,359,000 after purchasing an additional 57 shares during the period. CIBC Asset Management Inc boosted its holdings in Penumbra by 5.4% during the fourth quarter. CIBC Asset Management Inc now owns 1,183 shares of the company’s stock valued at $281,000 after purchasing an additional 61 shares in the last quarter. Finally, UMB Bank n.a. grew its stake in shares of Penumbra by 57.4% in the 4th quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $46,000 after purchasing an additional 70 shares during the period. Institutional investors own 88.88% of the company’s stock.

Wall Street Analysts Forecast Growth

PEN has been the topic of several recent analyst reports. StockNews.com downgraded Penumbra from a “buy” rating to a “hold” rating in a report on Friday, February 28th. Citigroup raised their price target on shares of Penumbra from $220.00 to $245.00 and gave the company a “neutral” rating in a report on Wednesday, December 11th. Royal Bank of Canada lifted their target price on Penumbra from $285.00 to $313.00 and gave the company an “outperform” rating in a research note on Wednesday, February 19th. Truist Financial lifted their price objective on Penumbra from $285.00 to $325.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. Finally, Bank of America began coverage on shares of Penumbra in a report on Friday, March 14th. They issued a “buy” rating and a $320.00 price objective on the stock. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $294.47.

Penumbra Price Performance

Penumbra stock opened at $267.16 on Friday. The stock’s fifty day moving average price is $274.55 and its two-hundred day moving average price is $242.90. The firm has a market cap of $10.29 billion, a PE ratio of 785.75, a price-to-earnings-growth ratio of 2.83 and a beta of 0.51. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25. Penumbra, Inc. has a one year low of $148.00 and a one year high of $310.00.

Penumbra (NYSE:PEN) last issued its earnings results on Tuesday, February 18th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.88 by $0.09. The company had revenue of $315.52 million during the quarter, compared to analysts’ expectations of $311.63 million. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. As a group, research analysts expect that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Insider Activity

In other Penumbra news, Director Arani Bose sold 12,000 shares of the stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $283.77, for a total transaction of $3,405,240.00. Following the transaction, the director now directly owns 314,819 shares in the company, valued at approximately $89,336,187.63. This represents a 3.67 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Harpreet Grewal sold 167 shares of the company’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $241.28, for a total transaction of $40,293.76. Following the transaction, the director now owns 8,530 shares in the company, valued at $2,058,118.40. This represents a 1.92 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 93,518 shares of company stock worth $26,400,219. Insiders own 5.00% of the company’s stock.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.